Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Eli Lilly and Company (NYSE:LLY) is one of the 10 Best American Stocks to Buy and Hold for the Next Decade. On May 31, 2026, Eli Lilly and Company (NYSE:LLY) announced results from the Phase 3 Libretto-432 clinical trial of Retevmo as adjuvant therapy versus placebo in patients with early-stage rearranged during transfection fusion-positive non-small […]
The seasonal strength lines up with major medical and scientific conferences that cluster during this period.
Johnson & Johnson (NYSE:JNJ) was among Jim Cramer’s stock calls on Mad Money, as he highlighted several opportunities in out-of-favor sectors. Cramer highlighted the company’s billion-dollar drugs and growing businesses, as he stated: So I’m going to do something completely out of favor and recommend one that we’re buying for the Charitable Trust gingerly, as […]
Eli Lilly and Company (NYSE:LLY) was among Jim Cramer’s stock calls on Mad Money, as he highlighted several opportunities in out-of-favor sectors. Cramer mentioned the stock while discussing the woes of the healthcare industry, as he said: Next worst is healthcare. Oh, this group has just been annihilated. I’ve never seen it trading this bad […]
LLY's 2026 deal-making spree spans vaccines, oncology and neuroscience, aiming to diversify growth beyond GLP-1s amid rising obesity competition.
Eli Lilly stock gains 14% in a month as strong Q1 results, obesity drug coverage expansion and promising retatrutide data fueled momentum.
TD Cowen expects around 59 million patients worldwide to be using GLP-1 therapies by the end of the decade, up sharply from its previous estimate of 46 million.
In late May and early June 2026, Eli Lilly reported strong Phase 3 results for obesity, diabetes and oncology drugs, broadened coverage of its full obesity portfolio by all three major U.S. pharmacy benefit managers, and added Sesame and WW International’s Weight Watchers Med+ programs to its LillyDirect digital platform to improve access and support for patients. Together, these developments deepen Lilly’s presence across the entire cardiometabolic care journey, from gene-editing and...
It's another step in Eli Lilly's quest to cement its lead in the chronic weight management market.
From hepatitis B to melanoma, recent study results show innovative approaches are gaining ground.
BRK.B, LLY and WMT headline top analyst reports, highlighting business strengths, growth drivers and key risks shaping their outlooks.
Competition is intensifying after WeightWatchers' Med+ program became available through LillyDirect.
Shares of personal wellness company WeightWatchers (NASDAQ:WW) jumped 6.3% in the afternoon session after the company announced its Weight Watchers Med+ program is now accessible through Eli Lilly's digital healthcare platform, LillyDirect.
Eli Lilly reported positive Phase 1b data for VERVE-102, a gene-editing cardiovascular therapy, raising fresh competitive pressure on CRISPR Therapeutics' CTX310 program. CRISPR Therapeutics (NasdaqGM:CRSP) is broadening beyond gene editing with the acquisition of CTX611, a phase 2 siRNA therapy targeting blood clotting. These developments arrive as large pharma and specialist biotech companies increase focus on genetic and RNA-based approaches to cardiovascular disease. For you as an...
Biopharma M&A has surged to $106 billion across 201 deals through early June 2026, putting the sector on track for its strongest full-year total since the 2019 pre-pandemic peak, CNBC reported.
Dow Jones futures fell slightly after hours, along with S&P 500 futures and Nasdaq futures. The May jobs report is on tap before Friday's open. The stock market saw the Dow Jones jump to a record high, aided by lower oil prices and Treasury yields.
Even without its metabolic business, management argues Eli Lilly (LLY) would be one of the fastest-growing pharmaceutical companies in the industry. This is not a single-product story. The company's immunology, oncology, and neuroscience medicines collectively grew by 160%, showing the depth of its R&D engine.
Berkshire Hathaway, Eli Lilly and Walmart headline new analyst reports, highlighting growth drivers, opportunities and key risks shaping their outlooks.
Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index climbing 3.2%
Eli Lilly stock is Thursday's IBD Stock Of The Day as the weight-loss behemoth deepens its focus on gene editing, vaccines and cancer.
WW International (NASDAQ:WW) has integrated its Weight Watchers Med+ offering with Eli Lilly’s (NYSE:LLY) LillyDirect healthcare platform, broadening access to its clinical weight management services for patients using or considering prescription obesity treatments. The collaboration connects LillyDirect users with Weight Watchers’ program, which combines GLP-1 medications with behavioral, nutritional and lifestyle support.
Eli Lilly knows that its GLP-1 windfall comes with an end date, so it is acting now to prepare.
The company cited uncertainty surrounding proposed healthcare and drug-pricing reforms.
Although Moderna has outperformed the broader health care sector over the last 12 months, analysts maintain a cautious stance on the stock’s future outlook.
The shares are up more than 13% this year, and the pharmaceutical company has several other factors that could drive its stock higher.
Lilly’s deal with Ascidian is one of several that the pharma giant has cut within the realm of genetic medicines.
Eli Lilly is far from a one-trick pony.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
